Filing Flows › Indivior Pharmaceuticals (INDV) › Q2 2026 › vs Q2 2025
Indivior Pharmaceuticals (INDV) Q2 2026 vs Q2 2025 (year over year)
Indivior Pharmaceuticals's revenue rose $41.0M (+14%) from $302M in Q2 2025 to $343M in Q2 2026. Gross margin 85.7% against 82.8% (+2.9 pts).
Indivior Pharmaceuticals, Q2 2026: revenue $343M (+14% year over year), operating margin 46.6%, net earnings $122M, operating cash flow $229M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 85.7% | 82.8% | +2.9 pts |
| Operating margin | 46.6% | 23.8% | +22.8 pts |
| Net margin | 35.6% | 6.0% | +29.6 pts |
| Free cash flow margin | 64.7% | 46.7% | +18.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $343M | $302M | $41.0M | +14% |
| Gross profit | $294M | $250M | $44.0M | +18% |
| Cost of revenue | $49.0M | $52.0M | −$3.0M | -6% |
| Operating profit | $160M | $72.0M | $88.0M | +122% |
| Operating expenses | $134M | $178M | −$44.0M | -25% |
| Pre-tax earnings | $160M | $62.0M | $98.0M | +158% |
| Net earnings | $122M | $18.0M | $104M | +578% |
| Income tax | $38.0M | $44.0M | −$6.0M | -14% |
| Depreciation & amortization | $2.0M | $2.0M | $0 | 0% |
| Share-based compensation | $11.0M | $8.0M | $3.0M | +38% |
| Working capital & other | $94.0M | $130M | −$36.0M | -28% |
| Operating cash flow | $229M | $158M | $71.0M | +45% |
| Free cash flow (OCF − capex) | $222M | $141M | $81.0M | +57% |
| Capital expenditures | $7.0M | $17.0M | −$10.0M | -59% |
Questions
How much did Indivior Pharmaceuticals's revenue grow year over year in Q2 2026?
Indivior Pharmaceuticals's revenue rose $41.0M (+14%) from $302M in Q2 2025 to $343M in Q2 2026. Gross margin 85.7% against 82.8% (+2.9 pts).